Search results for "Editor"

showing 10 items of 844 documents

Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?

2020

Nonalcoholic steatohepatitismedicine.medical_specialtyHepatologymedicine.diagnostic_testbusiness.industryMEDLINEMagnetic resonance imagingClinical trialEditorialText miningmedicinelcsh:Diseases of the digestive system. GastroenterologyRadiologylcsh:RC799-869businessHepatology Communications
researchProduct

El valencianisme lingüístic de Nicolau Primitiu Gómez Serrano

2012

Aquest article constitueix un estudi de les activitats més rellevants i la posició ideològica de Nicolau Primitiu Gómez Serrano al voltant del català de València: fixació de la toponímia del País Valencià, defensa i difusió de les Normes de Castelló, reivindicació de l’ús del valencià a l’escola i del seu ensenyament, promoció del Diccionari Català-Valencià-Balear d’Alcover-Moll, creació de plataformes editorials i teories sobre l’origen i el nom de la llengua dels valencians.

Normes de Castelló ensenyament del valencià toponímia Diccio-nari Català-Valencià-Balear editorial Sicània origen del valencià i nom de la llengualcsh:Language and Literaturelcsh:Philology. LinguisticsUNESCO::CIENCIAS DE LAS ARTES Y LAS LETRASlcsh:P1-1091LingüísticaFilologías:CIENCIAS DE LAS ARTES Y LAS LETRAS [UNESCO]lcsh:P
researchProduct

Editorial decisions: highlighting the role of systematic reviews

2018

En 2014, el doctor Gerard Urrútia del Centro Cochrane Iberoamericano - Institut d'Investigació Biomèdica Sant Pau, escribió unas líneas editoriales para la Revista Española de Nutrición Humana y Dietética1 en las que ponía en valor la necesidad de "incrementar el rigor científico tanto en la producción de estudios científicos, que proporcionen las bases para una toma de decisiones bien fundamentada, como en su divulgación mediante publicaciones científicas de calidad" en el ámbito de la nutrición y la dietética. Asimismo vaticinaba que "cabría esperar, por una parte, un creciente interés en la producción de revisiones sistemáticas por parte de profesionales de nuestro medio, también entre d…

Nutrition and DieteticsRC620-627Nutrition. Foods and food supplyDecisiones editoriales03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisMedicina Preventiva y Salud PúblicaTX341-641030212 general & internal medicinePsychologyNutritional diseases. Deficiency diseasesFood ScienceRevisiones sistemáticasRevista Española de Nutrición Humana y Dietética
researchProduct

Argullol a vueltas con la opinión pública

2007

OPINIÓN PÚBLICAVidal-Beneyto JoséEspacio públicodictaduraOpiniónTertuliasEl PaísHabermasRAFAEL ARGULLOLDescalificaciónPeriodistasImpugnaciónDiversidad opinativaEmpresariosArgullolOpinión publicadaOpinión de los públicosSondeosMario Vargas LlosaEditorialPiedra de toqueTribunaPolíticosSociedad mediática de masaObstinaciónSindicatosNotoriedadPublicaciones: Obra periodística: Cartas al director
researchProduct

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

2017

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

OncologyAdultMaleCancer Researchmedicine.medical_specialtyMyeloidAdolescentmedicine.medical_treatmentSalvage therapyHematopoietic stem cell transplantationOutcome (game theory)03 medical and health sciencesYoung Adult0302 clinical medicineText miningRecurrencehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansYoung adultLetter to the EditorAgedAged 80 and overSalvage Therapybusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle Agedmedicine.diseasePrognosisLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisFemalebusiness030215 immunologyLeukemia
researchProduct

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypometh…

2017

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents

OncologyAdultMalemedicine.medical_specialtyAntimetabolites AntineoplasticeducationAzacitidineChronic myelomonocytic leukemiaDecitabine03 medical and health sciences0302 clinical medicineMyelodysplastic–myeloproliferative diseaseshemic and lymphatic diseasesInternal medicinemedicineHumansLetter to the Editorhealth care economics and organizationsAgedHematologybusiness.industryMyelodysplastic syndromesTranslational biologyfood and beveragesLeukemia Myelomonocytic Chronic[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyDNA MethylationMiddle Agedmedicine.diseaseMyelodysplastic-Myeloproliferative DiseasesSurvival Analysis3. Good healthResponse assessmentLeukemiaTreatment OutcomeOncology030220 oncology & carcinogenesisMyelodysplastic SyndromesImmunologyAzacitidineFemalebusiness030215 immunologymedicine.drug
researchProduct

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology.

2021

Abstract The COVID-19 pandemic affected millions of people globally with lasting effects on society, patients, investigators and health institutions. Clinical trials, our best tool to improve cancer treatment for patients through testing the clinical value of a new treatment, have been affected by the pandemic. The pandemic footprint represents both a risk of compromising development of new therapies and an opportunity to elicit discussion over a portfolio of broader reforms, applicable irrespective of pandemics, in order to improve the design and implementation of clinical trials in oncology. The administrative load should be reduced, without affecting the quality of research and principle…

OncologyCancer ResearchTelemedicinemedicine.medical_specialtyOncologiamedia_common.quotation_subjectMedical Oncology:profesiones sanitarias::medicina::medicina interna::oncología médica [DISCIPLINAS Y OCUPACIONES]Quality of life (healthcare):características del estudio::estudio clínico::ensayo clínico [CARACTERÍSTICAS DE PUBLICACIONES]:Study Characteristics::Clinical Study::Clinical Trial [PUBLICATION CHARACTERISTICS]Internal medicinePandemic:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]medicinePandèmia de COVID-19 2020-HumansQuality (business):Health Occupations::Medicine::Internal Medicine::Medical Oncology [DISCIPLINES AND OCCUPATIONS]Pandemicsmedia_commonCOVID-19; Humans; Medical Oncology; Pandemics/prevention & control; SARS-CoV-2; TelemedicineSurrogate endpointSARS-CoV-2COVID-19:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]World populationTelemedicineClinical trialEditorialOncologyGood clinical practiceBusinessAssaigs clínicsESMO open
researchProduct

Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers

2011

[Background]: Germline mutations in the BRCA1 and BRCA2 genes are associated with increased risks of breast and ovarian cancers. Although several common variants have been associated with breast cancer susceptibility in mutation carriers, none have been associated with ovarian cancer susceptibility. A genome-wide association study recently identified an association between the rare allele of the single-nucleotide polymorphism (SNP) rs3814113 (ie, the C allele) at 9p22.2 and decreased risk of ovarian cancer for women in the general population. We evaluated the association of this SNP with ovarian cancer risk among BRCA1 or BRCA2 mutation carriers by use of data from the Consortium of Investi…

OncologyCancer Researchendocrine system diseasesGenes BRCA2Genes BRCA1Genome-wide association studyFAMILIES0302 clinical medicineRisk FactorsRetrospective StudieGenotypeOdds Ratioskin and connective tissue diseasesPOPULATIONGeneticsOvarian NeoplasmsAged 80 and overAllele0303 health scienceseducation.field_of_studyLikelihood FunctionsArticlesGERMLINE MUTATIONSMiddle AgedLikelihood Functionfemale genital diseases and pregnancy complications3. Good healthOncology030220 oncology & carcinogenesisFemaleChromosomes Human Pair 9HumanAdult[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]medicine.medical_specialtyHeterozygoteSUSCEPTIBILITY LOCIGenotypePROTEINSPopulationBiologyPolymorphism Single NucleotideBASONUCLIN-203 medical and health sciencesBreast cancerGermline mutationSDG 3 - Good Health and Well-beingInternal medicinemedicineBREAST-CANCERHumansGENOME-WIDE ASSOCIATIONeducationAllelesGerm-Line Mutation030304 developmental biologyRetrospective StudiesAgedIDENTIFICATIONRisk FactorOvarian NeoplasmEditorialsCancermedicine.diseaseMinor allele frequencyOvarian cancer
researchProduct

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

2013

Background: ER þ/HER2 � breast cancers have a proclivity for late recurrence. A personalised estimate of relapse risk after 5 years of endocrine treatment can improve patient selection for extended hormonal therapy. Methods: A total of 1702 postmenopausal ER þ/HER2 � breast cancer patients from two adjuvant phase III trials (ABCSG6, ABCSG8) treated with 5 years of endocrine therapy participated in this study. The multigene test EndoPredict (EP) and the EPclin score (which combines EP with tumour size and nodal status) were predefined in independent training cohorts. All patients were retrospectively assigned to risk categories based on gene expression and on clinical parameters. The primary…

OncologyCancer Researchmedicine.medical_specialtyAntineoplastic Agents HormonalReceptor ErbB-2AnastrozoleBreast NeoplasmsCell Growth ProcessesAnastrozoleBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsNitrilesClinical endpointHumansMedicineNeoplasm MetastasisProportional Hazards ModelsRandomized Controlled Trials as TopicRetrospective Studiesendocrine therapybusiness.industryProportional hazards modelGene Expression ProfilingCell DifferentiationRetrospective cohort studyTriazolesPrognosismedicine.diseaseSurgeryClinical triallate relapseTamoxifenTreatment OutcomeEditorialClinical Trials Phase III as TopicReceptors EstrogenOncologyClinical StudyHormonal therapyFemaleNeoplasm Recurrence LocalEndoPredictbusinessTamoxifenSignal Transductionmedicine.drugBritish Journal of Cancer
researchProduct

Letter to the Editor regarding the paper by Aurilio et al., A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth f…

2014

Sir,We have read with great interest the article in press ofAurilio et al., A meta-analysis of oestrogen receptor, pro-gesterone receptor and human epidermal growth factorreceptor 2 discordance between primary breast cancerand metastases (http://dx.doi.org/10.1016/j.ejca.2003.10.004), which will appear in Eur J Cancer. In the paper,the Authors have performed a meta-analysis of the stud-ies published in the literature concerning the discor-dance rate in oestrogen receptor (ER), progesteronereceptor (PgR) and HER2 status between primarytumour and corresponding relapse. It is well known thata considerable controversy concerns the issue of hor-mone receptors (HRs) expression as well as HER2 sta…

OncologyCancer Researchmedicine.medical_specialtyPathologyLetter to the editorBreast NeoplasmsSettore MED/08 - Anatomia PatologicaErbB-2breast cancer metastases oestrogen receptor human epidermal growth factor receptor 2Internal medicineProgesterone receptorReceptorsmedicineHumansOestrogen receptorskin and connective tissue diseasesReceptorProgesteronebusiness.industryCancermedicine.diseaseEstrogenRegimenOncologyLOCALLY RECURRENT HORMONE-RECEPTOR HER2 STATUS IMPACTMeta-analysisBreast Neoplasms; Female; Humans; Receptor ErbB-2; Receptors Estrogen; Receptors ProgesteroneImmunohistochemistryFemalebusinessReceptor
researchProduct